Cytoskeleton dynamics are regulated by Src-family tyrosine kinases (SFKs) and c-Abl. We found that the SFK members Hck and c-Fgr regulate tyrosine phosphorylation of c-Abl and c-Abl associates with beta1 integrin-bound Hck or c-Fgr in murine macrophages. Studies with selective inhibitors and cells from SFK-deficient mice showed that c-Abl and SFK regulate migration and activation of the small GTPases Cdc42 and Rac in macrophages. Additionally, human neutrophil chemotactic activity was reduced by c-Abl inhibitors, and neutrophils from chronic myeloid leukaemia patients displayed an increased chemotactic ability. Hence, Src-family kinase and c-Abl cross-talk in the regulation of myeloid cell migration
The mechanism by which the ubiquitously expressed Src family kinases regulate mitogenesis is not wel...
The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-po...
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CM...
Cytoskeleton dynamics are regulated by Src-family tyrosine kinases (SFKs) and c-Abl. We found that t...
AbstractCytoskeleton dynamics are regulated by Src-family tyrosine kinases (SFKs) and c-Abl. We foun...
Src-family kinases (SFKs) regulate different granulocyte and monocyte/macrophage responses. Accumula...
SummaryIn classical descriptions of leukocyte chemokine signaling, Src family kinases are thought to...
© 2014 Kova´cs et al.Although Src family kinases participate in leukocyte function in vitro, such as...
The hallmark of chronic myelogenous leukemia (CML) is the Philadelphia chromosome, which arises from...
The chemotactic peptide formyl-methionyl-leucyl-phenilalanine (fMLP) triggers intracellular protein ...
<p>The Abl family of protein tyrosine kinases regulates diverse cellular processes by coordinating c...
AbstractThe c-Abl tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption ...
Leukocyte recruitment into inflamed tissue is highly dependent on the activation and binding of inte...
Although Src family kinases participate in leukocyte function in vitro, such as integrin signal tran...
The c-Abl tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption of these...
The mechanism by which the ubiquitously expressed Src family kinases regulate mitogenesis is not wel...
The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-po...
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CM...
Cytoskeleton dynamics are regulated by Src-family tyrosine kinases (SFKs) and c-Abl. We found that t...
AbstractCytoskeleton dynamics are regulated by Src-family tyrosine kinases (SFKs) and c-Abl. We foun...
Src-family kinases (SFKs) regulate different granulocyte and monocyte/macrophage responses. Accumula...
SummaryIn classical descriptions of leukocyte chemokine signaling, Src family kinases are thought to...
© 2014 Kova´cs et al.Although Src family kinases participate in leukocyte function in vitro, such as...
The hallmark of chronic myelogenous leukemia (CML) is the Philadelphia chromosome, which arises from...
The chemotactic peptide formyl-methionyl-leucyl-phenilalanine (fMLP) triggers intracellular protein ...
<p>The Abl family of protein tyrosine kinases regulates diverse cellular processes by coordinating c...
AbstractThe c-Abl tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption ...
Leukocyte recruitment into inflamed tissue is highly dependent on the activation and binding of inte...
Although Src family kinases participate in leukocyte function in vitro, such as integrin signal tran...
The c-Abl tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption of these...
The mechanism by which the ubiquitously expressed Src family kinases regulate mitogenesis is not wel...
The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-po...
The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CM...